###### Strengths and limitations of this study

-   This large consecutive Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography (CARDIIGAN) patient group has good and detailed data, especially on coronary arteries and past interventions; thus, it is possible to address many relevant clinical research questions.

-   Several possible sources of selection bias are ruled out through elective 'all-comer' recruitment in routine practice.

-   There are no data on non-invasive diagnostic results before inclusion in the cohort and no storage of serum and urine.

-   This is a single-centre cohort, so external validity can be questionable with certain topics.

-   Some data are missing due to limited resources during daily routine.

Introduction {#s1}
============

Cardiovascular diseases are prevalent worldwide, and is the leading cause of death both in men and women in Austria.[@R1] Particularly for coronary artery disease (CAD), up to now research into the determinants, such as the Framingham Heart Study, has focused mainly on aetiology and prognosis,[@R3] and only few studies pertain to the predictors of diagnosis or severity of angiographically ascertained CAD in larger cohorts.

Originally the cohort was implemented as a screening programme to attain more insights into the set of risk factors and their relation to and their predictive value to the diagnosis and severity of CAD of consecutive patients referred for elective cardiac catheterisation to the Department of Cardiology at the University Hospital of Innsbruck, Austria. An additional aim was quality inspection on risk factor control and therapeutic strategies. Additionally, the programme enables comparison of the patients in the referral area of our hospital with those of other studies and registries, thereby optimising the risk management of our patients. A few years ago, retrospectively more information on coronary arteries was extracted and survival information from the regional social security registry was linked,[@R4] thereby finally establishing the Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography (CARDIIGAN) cohort. It was then that the potential of this cohort was fully recognised and research questions were further worked out, starting with the diagnostic ones.

Cohort description {#s2}
==================

Initial patient inclusion was between February 2004 and April 2008, resulting in a total of 8296 consecutive patients of 18 years and older electively referred for invasive evaluation of a suspected CAD. After informed consent was obtained, they received conventional coronary angiography (CA) by the standard Judkins technique, predominantly via the femoral approach. The participation of a patient did not lead to any excess risks. Blood chemistry was done in the context of daily clinical routine, as was the execution of the study itself.

The cohort was 65% male and on average 63 years of age (between 18 and 91 years). A part of the cohort consists of patients with history of coronary revascularisation (percutaneous coronary intervention or coronary artery bypass grafting). This subgroup with 1897 persons has a higher male proportion of 75% with similar age (average of 64 years, between 28 and 91 years). Another, partly overlapping subgroup of CARDIIGAN has CAD as the leading diagnosis (n=7081), at the exclusion of those referred for cardiac catheterisation due to a specific extracardiac condition (eg, solid organ transplantation) or cardiac disease other than CAD (such as heart transplantation or valvular and congenital heart disease). Of these patients with CAD, 5931 (84%) presented for the first time with this diagnosis. Since the University Clinic Innsbruck serves as a secondary as well as a tertiary hospital, a portion of the cohort members came from outside the primary catchment area (thereof nearly a quarter from abroad) of the regional social security service of Tyrol. This regional system is the source of the data on vital status. Thus these data are available for about 84% of the patients, the so-called 'local' patient group ([figure 1](#F1){ref-type="fig"}). Many of the other 16% of patients are typical of the tourism in this region and would probably often be incomparable with patients of cardiology clinics elsewhere.

![Subgroups of the CARDIIGAN cohort. The term 'local' indicates that survival data are available from the regional social security system. CABG, coronary artery bypass grafting; CAD, coronary artery disease; CARDIIGAN, Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography; PCI, percutaneous coronary intervention.](bmjopen-2018-021808f01){#F1}

Most data entry was done shortly after the patient was presented to the clinic. A part of the information (detailed laboratory data) was extracted from patients' charts after discharge and another part (final CA report) retrospectively, when the large potential of the cohort was realised and more details on the arteries deemed invaluable for relevant research questions. Also, a first record linkage was performed to assess survival status, with the date and cause of death, of the 'local' part of the CARDIIGAN cohort. Thereby there is information on survival of the highest possible quality,[@R5] available up to 1 January 2014, resulting in over 5 years of follow-up per person. During the first 5 years 13% had died. More linkage is now planned to update information on survival status, but also to assess the status of other events. Particularly data on various cardiovascular disease outcomes are to be gathered to enable appraisal of subsequent manifestations of arterial diseases.

Since the data documentation had to fit into the daily routine with limited time resources, some entries were incomplete and thereby a part of the data are missing. Of the clinical data 2.7% were lost, which concerns some 59% of the 8296 patients. As for the medication information, the documentation occurred suboptimally and so 47% was missing. The problem of missing values will be handled by applying multiple imputation techniques.[@R7]

[Table 1](#T1){ref-type="table"} shows the characteristics of the included patients, and basic data include residence, sex, age, height, weight and smoking status. Also symptoms of angina pectoris according to the so-called Canadian Cardiovascular Society score,[@R9] hypertension (\<140/90 mm Hg or relevant medication[@R10]), diabetes mellitus (fasting plasma glucose ≥126 mg/dL or medication[@R11]) and family history of premature myocardial infarction (first degree: male relative at age \<55 years, female relative at age \<65 years[@R12]) have been documented, as well as seven types of medication (antianginal, antihypertensive and lipid-lowering). On the laboratory parameters, there are 15 different parameters, including lipids. Detailed information on the three major coronary arteries and their main side branches, including the extent and severity of atherosclerotic obstructions and prior or current interventions, is available. Stenoses of the arteries were categorised into 0%, less than 50%, 50%--70% and over 70% obstruction. This enables categorisation of CAD into none, non-obstructive, and one-vessel, two-vessel or three-vessel disease. Other outcome measures are proposed treatment and survival status as of 31 December 2013, with date and cause of death.

###### 

Characteristics of the cohort participants in CARDIIGAN (n=8296)

  -----------------------------------------------------------------------------------------------------------------------
  Characteristics                                                        Specifics                          Missing (n)
  ---------------------------------------------------------------------- ---------------------------------- -------------
  Sex                                                                    Female: 2908 (35%)\                0
                                                                         Male: 5388 (65%)                   

  Age at baseline (years),\                                              63 (11)                            0
  mean (SD)                                                                                                 

  Residence                                                              Tyrol: 6949 (84%)\                 0
                                                                         Rest of Austria: 1027 (12%)\       
                                                                         Foreign: 320 (4%)                  

  Height (m),\                                                           1.71 (0.09)                        117
  mean (SD)                                                                                                 

  Weight (kg),\                                                          78.4 (14.9)                        118
  mean (SD)                                                                                                 

  Smoking status                                                         Never: 3660 (52%)\                 1212
                                                                         Former: 1929 (27%)\                
                                                                         Current: 1495 (21%)                

  Angina pectoris complaints                                             None: 3671 (44%)\                  0
                                                                         Stable: 2986 (36%)\                
                                                                         Unstable: 1269 (15%)\              
                                                                         Atypical: 370 (4%)                 

  Myocardial infarction                                                  None: 6523 (79%)\                  0
                                                                         STEMI: 459 (6%)\                   
                                                                         NSTEMI: 631 (8%)\                  
                                                                         MCI: 683 (8%)                      

  Valvular/congenital heart disease                                      No: 6395 (87%)\                    944
                                                                         Yes: 957 (13%)                     

  Cardiomyopathy                                                         No: 3793 (86%)\                    3909
                                                                         Yes: 594 (14%)                     

  Solid organ transplantation                                            No: 8128 (98%)\                    0
                                                                         Yes: 168 (2%)                      

  Hypertension                                                           No: 2227 (27%)\                    0
                                                                         Yes: 6069 (73%)                    

  Diabetes mellitus                                                      No: 6902 (83%)\                    0
                                                                         Yes: 1394 (17%)                    

  Family history of myocardial infarction\                               No: 6532 (79%)\                    0
  (first-degree relative: male \<55 years; female \<65 years)            Yes: 1764 (21%)                    

  Lipid-lowering medication: statin                                      No: 2521 (46%)\                    2808
                                                                         Yes: 2967 (54%)                    

  Antihypertension/anti-anginal\                                         No: 1141 (20%)\                    2721
  medication                                                             Yes: 4434 (80%)                    

  Total cholesterol (mg/dL), mean (SD)                                   193 (45)                           585

  HDL cholesterol (mg/dL), mean (SD)                                     54.9 (17.0)                        741

  LDL cholesterol (mg/dL),\                                              123 (38)                           756
  mean (SD)                                                                                                 

  Triglycerides (mg/dL),\                                                126 (91--175)                      591
  median (IQR)                                                                                              

  Fibrinogen (mg/dL),\                                                   367 (297--459)                     265
  median (IQR)                                                                                              

  C reactive protein (mg/dL),\                                           0.28 (0.12--0.70)                  207
  median (IQR)                                                                                              

  Prothrombin time (%), mean (SD)                                        103 (13)                           151

  Thrombocytes (×1000 U/µL), mean (SD)                                   233 (67)                           147

  Haemoglobin (g/dL), mean (SD)                                          14.3 (2.3)                         119

  Creatinine (mg/dL), mean (SD)                                          1.07 (0.72)                        105

  Gamma-glutamyltransferase (U/L),\                                      33 (21--54)                        321
  median (IQR)                                                                                              

  Uric acid (mg/dL), mean (SD)                                           6.33 (1.76)                        970

  Urea (mg/dL), median (IQR)                                             35.4 (29.1--44.4)                  248

  Maximum degree of stenosis                                             None: 2029 (25%)\                  226
                                                                         \<50%: 1588 (20%)\                 
                                                                         ≥50%--70%: 296 (4%)\               
                                                                         ≥70%: 4157 (52%)                   

  Number of stents                                                       None: 5918 (76%)\                  556
                                                                         1: 1398 (18%)\                     
                                                                         ≥2: 424 (5%)                       

  Number of bypass                                                       None: 7330 (94%)\                  527
                                                                         ≥1: 439 (6%)                       

  Cause of death (up until 31 December 2013) with complete ICD-10 code   Alive: 5366 (77%)\                 1347
                                                                         Cardiovascular death: 746 (11%)\   
                                                                         Other causes: 837 (12%)            
  -----------------------------------------------------------------------------------------------------------------------

CARDIIGAN, Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography; HDL, high-density lipoprotein; ICD-10, International Classification of Diseases, tenth revision; LDL, low-density lipoprotein; MCI, myocardial infarction; NSDTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

Patient and public involvement {#s2a}
------------------------------

Patients were not involved in the development and design of the project.

Findings to date {#s2b}
----------------

In a first publication, even before the end of the inclusion period, the results on the association of high-density lipoprotein (HDL) cholesterol and C reactive protein in relation to angiographically evaluated CAD were presented and showed that the two biomarkers seem to have an important independent association with the prevalence of the disease ([table 2](#T2){ref-type="table"}).[@R13] More recently, a small study was done focusing on sex differences concerning CAD and cardiovascular risk factors: especially the impact of smoking and hypercholesterolaemia seems to differ between men and women.[@R14]

###### 

Extract of the multivariable results from Alber *et al* [@R13]

  All patients                        CAD vs non-CAD   Wald statistic   
  ----------------------------------- ---------------- ---------------- -------
  Age (per year)                      1.058            1.051 to 1.066   247.7
  Male gender                         2.753            2.371 to 3.197   175.9
  HDL cholesterol (per mg/dL)         0.976            0.971 to 0.982   77.3
  Prior statin use                    1.751            1.511 to 2.029   55.3
  Smokers                             1.720            1.396 to 2.118   25.9
  Hypertension                        1.494            1.244 to 1.793   18.5
  Diabetes                            1.539            1.250 to 1.894   16.5
  C reactive protein (per log unit)   1.343            1.158 to 1.558   15.1
  Total cholesterol (per mg/dL)       1.003            1.001 to 1.005   9.2
  Triglycerides (per log unit)        0.917            0.621 to 1.355   0.2

Reproduced with permission from the *European Journal of Clinical Investigation*. 2008. The Authors. Journal Compilation 2008 Blackwell Publishing.

CAD, coronary artery disease; HDL, high-density lipoprotein.

After completion of patient recruitment and data management processes (including survival data linkage), the focus was on diagnostic prediction modelling. An interim study was presented at a meeting of the Austrian Society of Cardiology[@R15] and recently a full manuscript was published[@R16]: validation of an existing CAD diagnosis model showed moderate performance, but extension with HDL and LDL cholesterol, fibrinogen and C reactive protein led to a relevant extra net benefit. After this study a more refined polytomous regression analysis was done to predict five ordinal categories of CAD diagnosis, thus enabling a better treatment decision and possibly making some future angiographies unnecessary (accepted publication in Int J Cardiol 2018 [doi:10.1016/j.ijcard.2018.05.092](http://dx.doi.org/10.1016/j.ijcard.2018.05.092)).[@R17] Currently we are analysing data on chronic kidney disease to assess the associations of this disease, severity of CAD and mortality as inspired by the work of Brand *et al* [@R19] and our own previous work.[@R20] Other ideas involve complications,[@R21] in particular bleedings,[@R22] competing risks in mortality[@R23] and cost-effectiveness,[@R27] especially in the context of prioritisation of vascularisation.[@R29]

Strengths and limitations {#s2c}
-------------------------

It is unfortunate that survival assessment is not possible for the complete cohort; it is restricted to 84% of the participants. Actually it only involves those people who are residents of Tyrol, so the results apply to a clearly defined group and generalisability is probably not compromised in this respect. Another weakness is the absence of a personal follow-up of patients due to limited available resources at discharge. However, a very good alternative is the feasible and proven record linkage option. It is also unfortunate that there is a lack of information on non-invasive diagnostic modalities and results, since these might be relevant in the diagnostic work-up. This, and other aspects of the healthcare system, might lead to some selective referral bias, and one must be careful when interpreting the results. On the other hand, possible selection is counteracted because of the patients being assigned to a wide range of doctors, that is, general practitioners, internists and cardiologists. Ideally, research possibilities would have been enhanced if serum and urine could have been stored at the time to enable future additional laboratory tests, making it possible to include various novel biomarkers currently being introduced in this field.[@R31] Furthermore, we are inevitably confronted with missing information since the daily routine did not always allow complete registration of data; however, there are statistical imputation techniques to compensate for this limitation.

As for the strengths, this consecutive patient group comprises a large clinical cohort with 5--10 years of follow-up, with good and detailed data. The study involves an elective 'all-comer' recruitment, which excludes some potential sources of selection bias. Also, the study represents routine practice and therefore allows the assessment of the effectiveness of certain procedures, as opposed to the ideal case scenarios. Particularly valuable are the data on various routine laboratory results and extensive information on the arteries and past interventions.

Collaboration {#s3}
=============

Cooperation with other researchers is very much favoured. A contact has already been established with a local neurological research group. Furthermore, international participation is being searched for with experts in various fields. Particularly Ewout Steyerberg, professor of clinical biostatistics and medical decision making and one of the leading scientists in clinical prediction models,[@R32] has been welcomed to theoretically strengthen our research group. Also, Ben van Calster has been involved for his expertise on multinomial risk models.[@R33] Collaboration with other research groups with comparable data to enable external validation studies would be beneficial to further the prediction modelling plans. For more information the corresponding author (ME) can be contacted (Michael.Edlinger\@i-med.ac.at).
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